If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Administration on Alternate Days
Forsteo is not registered for administration on alternate days and this type of dosing is not recommended. Lilly-sponsored clinical trials have only evaluated the efficacy and safety of once-daily administration of teriparatide
Further
Information
When
the individual clinical decision was made to start a treatment with
teriparatide in a patient, the recommended dose is 20 mcg
teriparatide once daily since the summary of product information does
not list other doses of teriparatide for particular situations or
specific patient populations.1
Posology
according to Summary of Product Characteristics
The
recommended dose of Forsteo is 20 micrograms administered once
daily.1
The
maximum total duration of treatment with Forsteo should be 24 months.
The 24-month course of Forsteo should not be repeated over a
patient’s lifetime.1
Patients
should receive supplemental calcium and vitamin D supplements if
dietary intake is inadequate.1
Following
cessation of Forsteo therapy, patients may be continued on other
osteoporosis therapies.1
References
1.
Forsteo [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Date of Last Review:February 10, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com